CCL3 and neoplasm: In another cohort of mice, we observed a significant reduction in tumor size in the a-TEA-LS + a-PD-L1 combination group at an earlier time of tumor harvest as compared to monotherapy-treated controls (Figure 2D) along with a significant increase in several effector proteins including MIP-1α/CCL3, MIP-1β/CCL4, and IFN-γ following a-TEA-LS + aPD-L1 (Figure 2E).